Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/56279
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPannipa Suwannasomen_US
dc.contributor.authorYohei Sotomien_US
dc.contributor.authorHiroki Tateishien_US
dc.contributor.authorErhan Tenekeciogluen_US
dc.contributor.authorYaping Zengen_US
dc.contributor.authorRobin P. Kraaken_US
dc.contributor.authorJoanna J. Wykrzykowskaen_US
dc.contributor.authorRobbert J. De Winteren_US
dc.contributor.authorPatrick W. Serruysen_US
dc.contributor.authorYoshinobu Onumaen_US
dc.date.accessioned2018-09-05T03:12:16Z-
dc.date.available2018-09-05T03:12:16Z-
dc.date.issued2016-05-03en_US
dc.identifier.issn17447593en_US
dc.identifier.issn17425247en_US
dc.identifier.other2-s2.0-84961205510en_US
dc.identifier.other10.1517/17425247.2016.1153062en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84961205510&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/56279-
dc.description.abstract© 2016 Informa UK Limited. Introduction: Theoretical advantages of fully bioresorbable scaffold (BRS) stem from transient vessel support without rigid caging. Therefore, it could reduce long-term adverse events associated with the presence of foreign materials.Areas covered: This article will provide an overview of: drug-eluting BRS for various applications in the treatment of vascular disease; The mechanisms of active agent release from such scaffolds; currently available drug-eluting BRS and their future applications are also discussed.Expert opinion: The current BRS have been developed in order to achieve optimal vascular patency while providing long-term safety. The clinical efficacy and safety of BRS in coronary treatment have been reported as equal to that of the current metallic drug eluting stents in simple lesions. The application of BRS can potentially be expanded to other vascular beds. The research in bioengineering for the appropriate materials should not only focus on biocompatibility but also should be tailored according to the sites of implantation, which may require different strength and supporting period. The ultimate goal in this field is to develop a biocompatible device that provides equivalent and complementary therapy to other devices, and is able to disappear when the mechanical support and drug delivery are no longer required.en_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleBioresorbable drug-eluting scaffolds for treatment of vascular diseaseen_US
dc.typeJournalen_US
article.title.sourcetitleExpert Opinion on Drug Deliveryen_US
article.volume13en_US
article.stream.affiliationsAcademic Medical Centre, University of Amsterdamen_US
article.stream.affiliationsErasmus University Medical Centeren_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsImperial College Londonen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.